Amlitelimab

• A study of different investigational treatments in people with the interstitial lung disease that accompanies scleroderma (CONQUEST) Recruiting
  2023-507129-40-00 Phase II 11 countries Scleroderma Research Foundation
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab on background topical corticosteroids therapy in participants aged 1… Recruiting
  2023-508099-12-00 Phase III 7 countries Sanofi-Aventis Recherche & Developpement
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting
  2023-506548-18-00 Phase II/III 13 countries Sanofi-Aventis Recherche & Developpement
• A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended
  2023-508096-36-00 Phase III 11 countries Sanofi-Aventis Recherche & Developpement
• A Phase 2a/b study of the efficacy and safety of subcutaneous amlitelimab in adults with non-responsive celiac disease Ended
  2024-511213-38-00 Phase II 12 countries Sanofi-Aventis Recherche & Developpement
• Long-term safety and efficacy evaluation of subcutaneous amlitelimab in adult participants with moderate to severe asthma who completed trea… Ended
  2023-503385-24-00 Phase II 3 countries Sanofi-Aventis Recherche & Developpement
• Open label, long-term study evaluating safety and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate… Ended
  2022-502188-39-00 Phase II 8 countries Sanofi-Aventis Research & Development
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in adult participants with severe … Ended
  2024-511225-64-00 Phase II 8 countries Sanofi-Aventis Recherche & Developpement
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop… Ended
  2023-506558-20-00 Phase III 6 countries Sanofi-Aventis Recherche & Developpement
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended
  2022-501196-41-00 Phase III 4 countries Sanofi-Aventis Recherche & Developpement
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended
  2023-506557-38-00 Phase III 7 countries Sanofi-Aventis Research & Development
• Proof-of-concept study evaluating subcutaneous amlitelimab in adult participants with moderate to severe hidradenitis suppurativa. Ended
  2023-505803-22-00 Phase II 7 countries Sanofi-Aventis Research & Development
• Dose ranging study of amlitelimab in adult participants with moderate-to-severe asthma Ended
  2024-510641-33-00 Phase II 3 countries Sanofi-Aventis Recherche & Developpement

Showing 1–13 of 13 trials